Table 3.
Univariate analysis of MACE in the subgroups of the study population
| MACE | |||
| Subgroups | n | Survival (%) | p |
| Demographic characteristics | |||
| Males/Females | 779/184 | 78.8/80.6 | 0.631 |
| Age ≥ 65/< 65 years | 516/447 | 79.4/78.6 | 0.622 |
| Medical history | |||
| Hypertension yes/no | 405/558 | 77.1/80.2 | 0.852 |
| Diabetes mellitus yes/no | 123/840 | 73.7/79.9 | 0.481 |
| Hypercholesterolemia yes/no | 465/498 | 83.0/76.0 | 0.124 |
| Past or current smokers yes/no | 491/472 | 76.5/81.9 | 0.380 |
| BMI ≥ 25/< 25 (kg/m2) | 619/344 | 79.1/78.7 | 0.253 |
| Family history of MI yes/no | 272/691 | 78.5/79.4 | 0.401 |
| Prior MI yes/no | 297/666 | 82.0/77.9 | 0.292 |
| Prior PCI yes/no | 128/835 | 76.3/79.6 | 0.988 |
| Prior CABG yes/no | 89/874 | 71.3/79.9 | 0.564 |
| GP III a polymorphism | |||
| A1A1/A1A2/A2A2 | 690/248/25 | 78.3/80.6/91.7 | 0.777 |
| Coronary artery vessels diseased | |||
| Single+two-/three-vessel disease | 746/217 | 80.2/75.3 | 0.109 |
| LVEF ≥ 40%/< 40% | 808/155 | 80.4/73.5 | 0.012 |
| Therapy | |||
| ACE inhibitor yes/no | 316/647 | 69.2/81.9 | 0.062 |
| Beta-blocker yes/no | 546/417 | 74.9/81.3 | 0.262 |
| Statin yes/no | 334/629 | 76.5/79.2 | 0.770 |
| Therapy during follow-up | |||
| Statin yes/no | 462/501 | 82.6/76.2 | 0.031 |
| ACE inhibitor yes/no | 338/625 | 89.3/73.3 | < 0.001 |
| Beta-blocker yes/no | 580/383 | 86.5/69.3 | < 0.001 |
ACE, angiotensin converting enzyme; BMI, body mass index; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.